Tuberculosis is one of the most important global health problems. The vast majority of TB cases are in developing countries and South Africa has an exceedingly high TB case rate. New drug treatment regimens for tuberculosis are a global priority. The current TB regimen is effective in drug sensitive disease but is not user friendly and requires prolonged observed therapy. Developing drug- resistance fueled by poor compliance to this complex regimen is a growing concern.
Our mandate at the CTBRI is to facilitate the development of innovative new drug compounds aimed at reducing duration of therapy, pill burden and improved patient outcomes. We have developed extensive clinical experience in conducting relevant and quality tuberculosis drug research.
Our particular strengths are
- An experienced team of dedicated research staff dedicated to improving quality of life in our patients living with tuberculosis.
- A proven patient recruitment network and established relationships with local TB authorities.
Excellent patient compliance profiles developed through our day to day experience with monitoring patients on clinical trials.
- Broad experience gained through an extensive network of collaborating institutions, funders and NGO’s.
- A proven academic record at the University of Cape Town Lung Institute.
- Extensive experience in bronchial lavage studies and lung immunology studies in tuberculosis.
- Access to a state of the art, FDA compliant digital database.
Our state of the art inpatient drug testing unit is situated on Level 1 of the UCT Lung Institute. Our medical staff of TB research sisters and an on-site clinicians and pulmonologists handle the clinical and regulatory aspects required for quality research. Two additional outpatient sites for Phase 111 clinical trials are managed from the UCT Lung Institute. We also are able to provide advice and guidance on investigating new treatments for multi drug resistant (MDR) tuberculosis.
Enquiries may be directed to: